DPX-rHA + DPX-FLU

**DPX-rHA + DPX-FLU** is a combination vaccine platform developed by BioVaxys using the proprietary DPX delivery system, integrating recombinant hemagglutinin (rHA) for influenza and a DPX-formulated influenza antigen (FLU). The DPX platform is a water-free lipid-in-oil formulation that creates a depot effect at the injection site, promoting sustained antigen presentation to immune cells and eliciting robust, durable antibody responses with a single intramuscular dose. Preclinical studies in murine models demonstrated that DPX-rHA generates higher and longer-lasting anti-HA antibody titers compared to alum-adjuvanted rHA vaccines, while DPX-FLU provided nearly 100% survival against live influenza strain challenges one month post-vaccination, outperforming alum-FLU controls across multiple strains.[1][2][4][6]